1. ALLA AKTIER
  2. NYHETER
  3. ASARINA PHARMA

Asarina Pharma

Nyheter Asarina Pharma Nyheter alla bolag

ASARINA PHARMA AB (PUBL) RELEASES ANNUAL REPORT 2023

MARKN.

(Stockholm, 4 June 2024) Asarina Pharma (“the Company”) today announces the release of its 2023 Annual Report.

Status and Outlook
Since completing the phase IIa study in April 2023, the Company has focused on finding a partner who can bring Sepranolone into the next clinical phase. The Company will continue to explore the potential for a partnership, i.e. a sale or out-licensing of its IP assets.

The Company believes that it can complete the partnering process with its current financial resources but there is no guarantee that it will not incur unexpected costs during this partnering process. In case of an unfavorable outcome of the partnering activities, the Company will initiate an orderly winding-down, which may include the sale of assets and/or liquidation.

The full Annual Report 2023 including CEO Statement and consolidated financial statements with notes is available on the Company’s website here:
https://asarinapharma.com/investors/financial-reports/

For further information, please contact:
Peter Nordkild, CEO, Asarina Pharma AB
Phone: +45 25 47 16 46
E-mail: peter.nordkild@asarinapharma.com

Jakob Dynnes Hansen, CFO, Asarina Pharma AB
Tel: +45 5132 3698
E-mail: jakob.dynnes@asarinapharma.com

The Company’s Certified Adviser is Carnegie Investment Bank AB (publ)

About Asarina Pharma
Asarina Pharma is a Swedish biotech company developing Sepranolone for allopregnanolone-induced stress- and compulsivity-driven disorders. Our product pipeline is built on over 40 years of research into allopregnanolone-related neurological disorders. With our new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) we aim to deliver a new generation of safe, efficacious drugs for neurological conditions from Tourette syndrome to Obsessive Compulsive Disorder that still lack safe, efficacious pharmaceutical treatments.

Attachments
Asarina Pharma Annual Report 2023 EN Master

Datum 2024-06-04, kl 22:54
Källa MFN
Bifogade filer
Asarina Pharma Annual Report 2023 EN Master
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!